The Cardiac Patch Company Just Spent Half Its Bank Account on a Different Kind of Patch

iRhythm Technologies, which makes the Zio patch that cardiologists prescribe when a Holter monitor is too short and a referral to an electrophysiologist is too much, has agreed to buy VitalConnect for $287.5 million.

That is not the weird part. The weird part is that VitalConnect raised $100 million from investors in February 2025. Eighteen months later, iRhythm is writing a check for nearly three times that amount.

The basic point is that this is not a revenue deal. It is a category deal.

iRhythm dominates continuous ambulatory ECG monitoring — the market where you stick a patch on someone's chest for up to 14 days and the device streams heart rhythm data to a cloud service that flags arrhythmias. It is a $200-plus million-per-quarter business, growing at roughly 20%, and iRhythm owns it. What iRhythm does not own is mobile cardiac telemetry — the market where a patient wears a device that streams vital signs in real time to a clinical monitoring center staffed by technicians who watch live. MCT is a bigger market, estimated at roughly $1.3 billion in 2025 and projected to approach $3 billion by 2035. And the incumbents — Philips, GE HealthCare, Baxter's Bardy Diagnostics — have occupied it for decades.

VitalConnect is the private company that has built the most credible product in the gap between those two worlds. Its VitalPatch monitors up to 11 physiological parameters in real time, works both in hospital and at home, and has been adopted at major systems including Brigham and Women's, Hackensack, and Northwell. iRhythm's answer to MCT so far has been the Zio AT, a newer product that has not yet shifted the category. Instead of proving Zio AT can displace Philips over the next five years, iRhythm decided to buy the company closest to that outcome.

The deal structure is straightforward: $237.5 million in cash, $50 million in iRhythm stock, expected to close by year-end. iRhythm also agreed to lend VitalConnect up to $30 million in interim working capital before the deal closes. The cash comes from iRhythm's balance sheet, where it held $591.3 million as of June 30. That means iRhythm is spending nearly 40% of its cash reserves on this acquisition. In the same announcement, the company beat Q2 revenue expectations ($224.2 million, up 20.1% year over year), raised full-year guidance to $880–$890 million, and set an adjusted EBITDA margin target of 13–14% for 2026, with a stated goal of reaching 15% by 2027.

This timing reads like a playbook. Announce the acquisition the day after a Q2 beat and a guidance raise. The street is in a celebratory mood, the stock is moving in your direction, and the market is less likely to scrutinize the multiple. The stock was up 3.1% on the day of the announcement and roughly 13% over the prior five days.

The multiple is the question. VitalConnect had roughly $50.6 million in annual recurring revenue in 2023. Its CEO said in 2023 that revenue had tripled from 2021 to 2022 and was on track to nearly double again in 2023. Even if revenue has grown another 50–100% since then — a generous assumption — the $287.5 million price tag implies something in the range of 3x to 5x trailing revenue. For a private company that was hoping to hit profitability in 2024, that is a premium acquisition. It is not an absurd one. Medtech platforms with strong distribution relationships can command those multiples when the buyer is paying for access to a category, not just for existing cash flow.

But here is the structural friction: MCT is a service business, not a patch business. The value in mobile cardiac telemetry does not live in the wearable sensor; it lives in the monitoring center, the technicians, the staffing, the 24/7 operations, and the hospital contracts. iRhythm has built its margins by keeping its model asset-light — patches go out, data comes in, AI-assisted algorithms do the interpretation. VitalConnect's real-time monitoring adds a layer of human-in-the-loop operations that iRhythm does not currently run at scale. Buying the technology is easy. Absorbing the service model without eroding the margin trajectory is the part that requires execution.

iRhythm's management says the deal is accretive and that it plans to preserve its 15% adjusted EBITDA margin target for 2027. That is a clean headline. The unspoken question is whether MCT economics, with their staffing-heavy cost structure, can be integrated into a company whose entire operating story has been about scaling software and diagnostics with minimal incremental cost per patient.

There is also the question of what VitalConnect's investors get out of this. The $100 million round in February 2025 was a mix of equity (led by Ally Bridge Group) and debt (from Trinity Capital), and it presumably came at a valuation meaningfully below $287.5 million. The existing shareholders — Revelation Partners, EW Healthcare Partners, Pacific General Ventures, and others from the Series F round in 2023 — are getting an exit after roughly a decade of patient capital. That is a good outcome for them. The question for iRhythm is whether the strategic upside — MCT market access, multi-vitals monitoring, hospital entry points — is worth the premium.

The simplest model is this: iRhythm needs to grow past its current $885 million revenue base into something approaching $1.2–$1.5 billion over the next several years to justify the stock price that preceded the announcement ($132, roughly $4.1 billion market cap). Organic growth at 20% gets you partway there. But the analyst consensus for next-year growth is already slowing to roughly 15%. Acquisitions are the difference between a company that grows into its multiple and one that gets priced down for deceleration. This deal is an attempt to buy the next growth curve.

The thing about cardiac monitoring is that it is becoming a continuum rather than a set of products. The patch is the entry point. The real-time monitor is the upsell. The multi-vitals biosensor is the platform. iRhythm has the patch locked up. Now it is buying its way into the rest of the chain.

Whether $287.5 million is the right price for that depends on whether iRhythm can run a service business as cleanly as it runs a diagnostic one. That is not a question you can answer from the press release. It is a question the integration will answer over the next two years.